33098-13-4 Usage
Uses
Used in Pharmaceutical Research and Development:
4-(4,5-DICHLORO-6-OXOPYRIDAZIN-1(6H)-YL)BENZENESULFONAMIDE is used as a research compound for its potential to inhibit the growth of a variety of cancer cells, making it a candidate for cancer therapy. Its sulfonamide moiety allows for possible interactions with various biological targets, contributing to its versatility in drug development.
Used in Cancer Therapy:
In the field of oncology, 4-(4,5-DICHLORO-6-OXOPYRIDAZIN-1(6H)-YL)BENZENESULFONAMIDE is used as an antifolate antibiotic, which can disrupt the synthesis of nucleic acids and proteins in cancer cells, thereby inhibiting their growth and proliferation.
Used in Medicinal Chemistry:
4-(4,5-DICHLORO-6-OXOPYRIDAZIN-1(6H)-YL)BENZENESULFONAMIDE is utilized as a starting material or intermediate in the synthesis of new pharmaceuticals, given its unique structural features and potential to be modified for specific therapeutic applications.
Used in Drug Design:
In the drug design industry, 4-(4,5-DICHLORO-6-OXOPYRIDAZIN-1(6H)-YL)BENZENESULFONAMIDE is used as a template for the development of novel drugs, leveraging its chemical properties to create molecules with improved pharmacological profiles and therapeutic effects.
Check Digit Verification of cas no
The CAS Registry Mumber 33098-13-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,3,0,9 and 8 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 33098-13:
(7*3)+(6*3)+(5*0)+(4*9)+(3*8)+(2*1)+(1*3)=104
104 % 10 = 4
So 33098-13-4 is a valid CAS Registry Number.
InChI:InChI=1/C10H7Cl2N3O3S/c11-8-5-14-15(10(16)9(8)12)6-1-3-7(4-2-6)19(13,17)18/h1-5H,(H2,13,17,18)
33098-13-4Relevant academic research and scientific papers
Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines
Krasavin, Mikhail,Shetnev, Anton,Baykov, Sergey,Kalinin, Stanislav,Nocentini, Alessio,Sharoyko, Vladimir,Poli, Giulio,Tuccinardi, Tiziano,Korsakov, Mikhail,Tennikova, Tatiana B.,Supuran, Claudiu T.
, p. 301 - 314 (2019/03/04)
An expanded set of pyridazine-containing benzene sulfonamides was investigated for inhibition of four human carbonic anhydrase isoforms, which revealed a pronounced inhibition trend toward hCA IX, a cancer-related, membrane-bound isoform of the enzyme. Comparison of antiproliferative effects of these compounds against cancer (PANC-1) and normal (ARPE-19) cells at 50 μM concentration narrowed the selection of compounds to the eight which displayed selective growth inhibition toward the cancer cells. More detailed investigation in concentration-dependent mode against normal (ARPE-19) and two cancer cell lines (PANC-1 and SK-MEL-2) identified two lead compounds one of which displayed a notable cytotoxicity toward pancreatic cancer cells while the other targeted the melanoma cells. These findings significantly expand the knowledge base concerning the hCA IX inhibitors whose inhibitory potency against a recombinant enzyme translates into selective anticancer activity under hypoxic conditions which are aimed to model the environment of a growing tumor.
